Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463556 | 1.00 | ALDH1A1 (0.58) | ALDH1A1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL4117018 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL4117015 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL5451648 | 0.83 | KDM4E (0.61) | ALDH1A1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL5451650 | 0.83 | KDM4E (0.61) | ALDH1A1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL5449601 | 0.82 | RPS6KA3 (0.45) | ALDH1A1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL5449606 | 0.82 | RPS6KA3 (0.45) | ALDH1A1KMT2AKDM4EHPGDMAPT | |
| SCHEMBL9362275 | 0.81 | KDM4E (0.65) | ALDH1A1KMT2AKDM4EHPGDCISD1 | |
| SCHEMBL9362272 | 0.81 | KDM4E (0.65) | ALDH1A1KMT2AKDM4EHPGDCISD1 | |
| SCHEMBL21457216 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KMT2AKDM4EHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1678138-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042488-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | ALDH1A1 743/4885KMT2A 1601/4885KDM4E 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.